

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: February 15, 2022
PDL Changes Effective Date: April 1, 2022



The following changes will be made to the Preferred Drug List (PDL), effective April 1, 2022, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
ANTIPSYCHOTICS, INJECTIBLE	INVEGA HAFYERA (paliperidone)
MISCELLANEOUS	CARBAGLU (carglumic acid)

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
ACNE, TOPICAL	WINLEVI (clascoterone)
ANTIBIOTICS, GI	AEMCOLO (rifamycin)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	EXKIVITY (mobocertinib)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	WELIREG (belzutifan)
ANTIMIGRAINE, PREVENTATIVE	QULIPTA (atogepant)
ANTIPSYCHOTICS	LYBALVI (olanzapine/samidorphan)
ATOPIC DERMATITIS	OPZELURA (ruxolitinib)
BILE SALTS	BYLVAY (odevixibat)
BILE SALTS	LIVMARLI (maralixibat)
IMMUNOSUPPRESANTS	REZUROCK (belumosudil)
MISCELLANEOUS	carglumic acid
OPHTHALMIC DRY EYE AGENTS	TYRVAYA (varenicline)
STIMULANTS AND RELATED AGENTS	AZSTARYS (serdexmethylphenidate/dexmethylphenidate)